



NZX Announcement

12 November 2019

Alternate Director Resignation

TruScreen Limited (NZX : TRU) (TruScreen or the Company) announces that Mr William Hunter resigned as an Alternate Director of the Company on 1 November 2019.

- ENDS -

For more information visit www.TruScreen.com or contact:

TruScreen

Anthony Ho

Chairman

tonyho@truscreen.com

Investors

Investor Relations

Phone: +61 2 9237 2801

TruScreen@we-buchan.com

About TruScreen:

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests including failed samples, poor patient follow up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen target market is lower income countries where no large scale cervical cancer screening programs and infrastructure are in place, such as; China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is EC certified for use throughout Europe and CFDA approved for sale in China. The global market potential for TruScreen is significant. At saturation, hundreds of millions of women could benefit from this accurate and inexpensive cervical cancer screening model.

For more information, visit our website at www.truscreen.com or on [LinkedIn](#) and [Facebook](#).